医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

2024年01月26日 AM06:15
このエントリーをはてなブックマークに追加


 

SHANGHAI & CAMBRIDGE, Mass.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, February 27, 2024. The Company will host a live conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET (9:00 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BIa1fd72e50c9e4117b696c49bdfa9f83b

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240126017959/en/

CONTACT

For more information, please contact:


Investor Relations:

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:

Shaun Maccoun / Xiaoyu Chen

+1 (415) 317-7255 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders